In this cohort study, 96.1–98.4% of the patients with HR-positive HER2-negative breast cancer were treated with neoadjuvant/adjuvant hormone therapy (54.5–70.1% aromatase inhibitors, 26.0–43.9% tamoxifen). The gene discussed is ERBB2; the disease is breast cancer.